Edition:
United Kingdom

MabVax Therapeutics Holdings Inc (MBVX.OQ)

MBVX.OQ on NASDAQ Stock Exchange Capital Market

2.36USD
16 Feb 2018
Change (% chg)

$1.58 (+204.48%)
Prev Close
$0.78
Open
$2.29
Day's High
$2.54
Day's Low
$2.29
Volume
28,828
Avg. Vol
20,061
52-wk High
$10.71
52-wk Low
$1.28

Latest Key Developments (Source: Significant Developments)

Mabvax Receives Notice Of SEC Investigation And Examination Of Certain Registration Statements
Tuesday, 30 Jan 2018 

Jan 30 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX RECEIVES NOTICE OF SEC INVESTIGATION AND EXAMINATION OF CERTAIN REGISTRATION STATEMENTS.MABVAX THERAPEUTICS - RECEIVED NOTICE SEC WAS CONDUCTING INVESTIGATION RELATING TO CERTAIN OF COMPANY'S REGISTRATION STATEMENTS.  Full Article

Mabvax Therapeutics Holdings Provides Business Strategy Update
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS HOLDINGS, INC. PROVIDES BUSINESS STRATEGY UPDATE.MABVAX THERAPEUTICS - ON TRACK TO EXECUTE CORPORATE AND CLINICAL MILESTONES IN FIRST HALF OF 2018.MABVAX - CURRENTLY IN "ADVANCED DISCUSSIONS" WITH A VARIETY OF INTERESTED PARTIES FOR POTENTIAL MULTIPLE DEAL PROPOSALS.  Full Article

MabVax Therapeutics Says Completed Patient Enrollment In Expanded Cohort Of Phase-1 Trial Testing MVT-5873
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND INITIAL PATIENT DOSING IN AN EXPANDED COHORT OF THE PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY.MABVAX THERAPEUTICS SAYS PLANS TO ANNOUNCE INTERIM SAFETY AND RECIST DATA Q1 2018.  Full Article

MabVax Therapeutics Files For Resale Of 16.6 Mln Shares Of Co's Common Stock
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Mabvax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS HOLDINGS INC FILES FOR RESALE OF 16.6 MILLION SHARES OF CO'S COMMON STOCK BY CERTAIN OF CO'S STOCKHOLDERS - SEC FILING.  Full Article

MabVax Completes Enrollment In Initial Cohort Of Its Cancer Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - MabVax Therapeutics Holdings Inc ::MABVAX THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN INITIAL COHORT OF MVT-1075 RADIOIMMUNOTHERAPY PHASE 1 TRIAL FOR THE TREATMENT OF PANCREATIC, COLON AND LUNG CANCERS.MABVAX THERAPEUTICS HOLDINGS INC - PLANS TO REPORT INTERIM RESULTS FROM STUDY EARLY IN Q1 OF 2018 AND CONTINUE DOSE ESCALATION PHASE OF PROGRAM.  Full Article

MabVax Therapeutics files for resale of 9.7 mln shares‍​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - MabVax Therapeutics Holdings Inc : :MabVax Therapeutics Holdings Inc - files for resale of 9.7 million shares of common stock of co by certain stockholders ‍​.  Full Article

MabVax Therapeutics files for resale of up to 6.97 mln shares of co's common stock‍​
Thursday, 19 Oct 2017 

Oct 20 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings Inc files for resale of up to 6.97 million shares of co's common stock‍​ by the selling stockholders - SEC filing‍​.  Full Article

Mabvax Therapeutics starts patient enrollment in phase 1 trial for cancer drug MVT-1075
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Mabvax Therapeutics Holdings Inc :Mabvax Therapeutics initiates patient enrollment in a phase 1 trial for MVT-1075, a new radioimmunotherapy treatment for advanced pancreatic, colon and lung cancers.Mabvax Therapeutics Holdings Inc - ‍Plans to announce topline interim results before year end from study​.  Full Article

MabVax stockholders approve remaining proposal at stockholders meeting
Saturday, 7 Oct 2017 

Oct 6 (Reuters) - MabVax Therapeutics Holdings Inc :MabVax Therapeutics Holdings - ‍resolution approved to implement, if necessary a reverse stock split of company's issued and outstanding common stock​.MabVax Therapeutics Holdings Inc - ‍ implementation of reverse stock split stock by a ratio of not less than 1 -for-2 and not more than 1 -for-20.  Full Article

MabVax Therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer
Tuesday, 7 Jun 2016 

Mabvax Therapeutics Holdings Inc :MabVax therapeutics expands patient enrollment in phase I trial for treatment of pancreatic cancer to Memorial Sloan Kettering Cancer Center.  Full Article

BRIEF-MabVax Therapeutics Says Reverse Stock Split Is Scheduled To Be Effective With Opening Of Trading On Feb 16

* MABVAX THERAPEUTICS SCHEDULES PREVIOUSLY ANNOUNCED 1-FOR-3 REVERSE STOCK SPLIT TO REGAIN COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT